Biotechnology company Nuclera and life sciences organisation Cytiva have announced a collaboration focused on accelerating the production, purification and characterisation of proteins required for drug research and development. The companies aim to enable this goal through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore surface plasmon resonance (SPR) technology. Read More
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President… Read More
Cytiva and BioCentriq, a new Jersey-based cell and gene therapy contract development and manufacturing organisation (CDMO), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership whose mission is to accelerate biopharmaceutical innovation. Viral clearance is a key regulatory requirement… Read More
Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, the companies aim to bring new bioprocess solutions to customers that use digitaliation, in-silico approaches, and virtual monitoring and control of experiments. … Read More
Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. DDW provides an update. GenScript Biotech Corporation: GenTitan Gene Fragments Synthesis service Powered by GenScript’s miniature semiconductor chip (MSC)… Read More
Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand. In January 2023, the life sciences business of Pall separated from Pall Corporation. Pall’s biotech portfolio is now a product family in… Read More
This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals. … Read More
Life sciences organisation Cytiva has acquired a new facility in Michigan US to help it expand its resins manufacturing operations outside of Sweden. The company’s new chromatography resins manufacturing site will be based in Muskegon, Michigan and forms part of Cytiva and Pall Corporation’s $1.5 billion capacity… Read More
Cytiva offer solutions to support work from biological research to clinical therapy, including tools for research, drug discovery, diagnostics and bioprocessing. Ryan Walker, the Sustainability Program Leader at Cytiva, discussed with DDW’s Megan Thomas the steps Cytiva is making to make their vision of a more sustainable… Read More
